Literature DB >> 24892980

Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.

Ruofeng Shang1, Xiuying Pu, Ximing Xu, Zhijun Xin, Chao Zhang, Wenzhu Guo, Yu Liu, Jianping Liang.   

Abstract

A series of novel pleuromutilin derivatives possessing thiadiazole moieties were synthesized via acylation reactions under mild conditions. The in vitro antibacterial activities of the derivatives against methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, Escherichia coli, and Streptococcus agalactiae were tested by the agar dilution method and Oxford cup assay. The majority of the tested compounds displayed moderate antibacterial activities. Importantly, the three compounds with amino or tertiary amine groups in their side chains, 11, 13b, and 15c, were the most active antibacterial agents. Docking experiments carried out on the peptidyl transferase center (PTC) of 23S rRNA proved that there is a reasonable direct correlation between the binding free energy (ΔGb, kcal/mol) and the antibacterial activity. Moreover, the pharmacokinetic profiles of 11 and 15c in rat were characterized by moderate clearance and oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24892980     DOI: 10.1021/jm500374c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.

Authors:  Shajila Siricilla; Katsuhiko Mitachi; Junshu Yang; Shakiba Eslamimehr; Maddie R Lemieux; Bernd Meibohm; Yinduo Ji; Michio Kurosu
Journal:  J Med Chem       Date:  2017-03-22       Impact factor: 7.446

2.  In vivo efficacy and toxicity studies of a novel antibacterial agent: 14-o-[(2-amino-1,3,4-thiadiazol-5-yl)thioacetyl] mutilin.

Authors:  Chao Zhang; Yunpeng Yi; Jiongran Chen; Rensheng Xin; Zhen Yang; Zhiting Guo; Jianping Liang; Ruofeng Shang
Journal:  Molecules       Date:  2015-03-24       Impact factor: 4.411

3.  Synthesis, biological activities and docking studies of pleuromutilin derivatives with piperazinyl urea linkage.

Authors:  Yuanyuan Zhang; Chuan Xie; Yang Liu; Feng Shang; Rushiya Shao; Jing Yu; Chunxia Wu; Xinghui Yao; Dongfang Liu; Zhouyu Wang
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

4.  Acute, subacute oral toxicity and Ames test of Py-mulin: an antibacterial drug candidate.

Authors:  Yuan Fan; Yunxing Fu; Yuhang Zhou; Yu Liu; Baocheng Hao; Ruofeng Shang
Journal:  BMC Pharmacol Toxicol       Date:  2022-01-04       Impact factor: 2.483

5.  Discovery of Novel Pleuromutilin Derivatives as Potent Antibacterial Agents for the Treatment of MRSA Infection.

Authors:  Han-Qing Fang; Jie Zeng; Shou-Kai Wang; Xiao Wang; Fang Chen; Bo Li; Jie Liu; Zhen Jin; Ya-Hong Liu; You-Zhi Tang
Journal:  Molecules       Date:  2022-01-29       Impact factor: 4.411

6.  An antimycobacterial pleuromutilin analogue effective against dormant bacilli.

Authors:  Maddie R Lemieux; Shajila Siricilla; Katsuhiko Mitachi; Shakiba Eslamimehr; Yuehong Wang; Dong Yang; Jeffrey D Pressly; Ying Kong; Frank Park; Scott G Franzblau; Michio Kurosu
Journal:  Bioorg Med Chem       Date:  2018-08-18       Impact factor: 3.641

7.  Cytochrome P450 inhibition potential and initial genotoxic evaluation of 14-O-[(4,6-diaminopyrimidine-2-yl)thioacetyl] mutilin.

Authors:  Yunxing Fu; Yunpeng Yi; Yuan Fan; Ruofeng Shang
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

8.  The Very First Modification of Pleuromutilin and Lefamulin by Photoinitiated Radical Addition Reactions-Synthesis and Antibacterial Studies.

Authors:  Son Thai Le; Dávid Páll; Erzsébet Rőth; Tuyen Tran; Nóra Debreczeni; Miklós Bege; Ilona Bereczki; Eszter Ostorházi; Márton Milánkovits; Pál Herczegh; Anikó Borbás; Magdolna Csávás
Journal:  Pharmaceutics       Date:  2021-11-28       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.